Sirolimus albumin-bound is under clinical development by Aadi Bioscience and currently in Phase I for Pulmonary Arterial Hypertension. According to GlobalData, Phase I drugs for Pulmonary Arterial Hypertension have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Sirolimus albumin-bound’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sirolimus albumin-bound overview
Sirolimus protein-bound particles for injectable suspension (Fyarro) is a macrolide lactams derivative drug belongs to immunosuppressive agent and an anti-neoplastic agent. It is formulated as powder for solution for intravenous route of administration. Fyarro is indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), hepatobiliary system tumor, melanoma, thyroid cancer, non-small cell lung cancer, esophageal cancer, pancreatic cancer, prostate cancer, colorectal tumor. It is also under development for solid tumors including hepatobiliary system tumor, melanoma, thyroid cancer, non-small cell lung cancer, esophageal cancer, pancreatic cancer, colorectal tumor with pathogenic inactivating alterations in TSC1 and TSC2 genes.e2. It was also under development for the treatment of relapsed/refractory multiple myeloma.
Aadi Bioscience overview
Aadi Bioscience, formerly Aerpio Pharmaceuticals Inc, is a clinical-stage biopharmaceutical company that focused on the developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. The company lead drug product, FYARROTM, (nab-sirolimus) is a form of sirolimus bound to albumin. It also focuswd on the drug discovery and development. The company’s FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with advanced unresectable or metastatic perivascular epithelioid cell tumor (PEComa). The company serves patients in the United States. Aadi Bioscience is headquartered in Los Angeles, California, the US
For a complete picture of Sirolimus albumin-bound’s drug-specific PTSR and LoA scores, buy the report here.